Stromal expression of miR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Melbø Jørgensen, Christian ^a   Andersen, Sigve ^a,b   Valkov, Andrej ^b   Dønnem, Tom ^a,b   Al Saad, Samer ^a,b   Kiselev, Yury ^a   Berg, Thomas ^b   Nordby, Yngve ^a,b   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b   Richardsen, Elin ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 21; MICRORNA; MIRN21 MICRORNA, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER TISSUE; CLINICAL FAILURE FREE SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FAILURE FREE SURVIVAL; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; DIAGNOSIS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; STROMA CELL; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; BIOMARKERS, TUMOR; COHORT STUDIES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; STROMAL CELLS; SURVIVAL RATE;

EID: 84913557571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113039     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90
2. Etzioni R, Mucci LA, Chen S, Johansson JE, Fall K, et al. (2012) Increasing use of radical prostatectomy for non-lethal prostate cancer in Sweden. Clin Cancer Res 15; 18(24): 6742-6747.
3. Breidablikk HJ, Meland E, Aakre KM, Forde OH (2013) PSA measurement and prostate cancer - overdiagnosis and overtreatment? Tidsskr Nor Laegeforen 16(3): 1711-1716.
4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2): 281-297.
5. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2): 215-233.
6. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of t Proc Natl Acad Sci U S A 2; 101(9): 2999-3004.
7. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, et al. (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer 5: 24.
8. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, et al. (2008) Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. The Prostate 68(11): 1152-1164.
9. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67(13): 6130-6135.
10. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14): 6029-33.
11. Hulf T, Sibbritt T, Wiklund ED, Bert S, Strbenac D, et al. (2011) Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC genomics 21; 12: 54.
12. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, et al. (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69(18): 7165-7169.
13. Ribas J, Lupold SE (2010) The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle 9(5): 923-929.
14. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, et al. (2010) miR-21: an oncomir on strike in prostate cancer. Mol Cancer 21; 9: 12.
15. Shi GH, Ye DW, Yao XD, Zhang SL, Dai B, et al. (2010) Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgenindependent prostate cancer PC3 cells. Acta Pharmacol Sin 31(7): 867-873.
16. Epstein JI, Allsbrook WC Jr., Amin MB, Egevad L, Committee IG (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American J Surg Pathol 29(9): 1228-1242.
17. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM (2012) Staging of prostate cancer. Histopathol 60(1): 87-117.
18. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, et al. (2003) Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 20; 103(5): 652-656.
19. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) Highthroughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20(10): 2417-2428.
20. Coppola V, De Maria R, Bonci D (2010) MicroRNAs and prostate cancer. Endocr Relat Cancer 29; 17(1): F1-17.
21. Gandellini P, Folini M, Zaffaroni N (2009) Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med 15(9): 381-390.
22. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumours defines cancer gene targets. Proc Natl Acad Sci U S A 14; 103(7): 2257-2261.
23. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68(15): 6162-6170.
24. Li T, Li D, Sha J, Sun P, Huang Y (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 5; 383(3): 280-285.
25. Li T, Li RS, Li YH, Zhong S, Chen YY, et al. (2012) miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 187(4): 1466-1472.
26. Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, et al. (2013) Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis 4: e684.
27. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, et al. (2012) Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 14: 159-167.
28. Yao Q, Cao S, Li C, Mengesha A, Kong B, et al. (2011) Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer 128: 1783-1792.
29. Mohler JL (2010) NCCN clinical practice guidelines in oncology on prostate cancer. Journal of the National Comprehensive Cancer Network: JNCCN 8(2): 145.
30. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, et al. (2004) Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100(11): 2362-2366.